IN2012DN01285A - - Google Patents

Info

Publication number
IN2012DN01285A
IN2012DN01285A IN1285DEN2012A IN2012DN01285A IN 2012DN01285 A IN2012DN01285 A IN 2012DN01285A IN 1285DEN2012 A IN1285DEN2012 A IN 1285DEN2012A IN 2012DN01285 A IN2012DN01285 A IN 2012DN01285A
Authority
IN
India
Prior art keywords
nitrite
nitrate
subject
compound
angiogenesis
Prior art date
Application number
Inventor
Fujimori Junya
Baba Hidekazu
Murata Toshinori
Original Assignee
Air Water Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Air Water Inc filed Critical Air Water Inc
Publication of IN2012DN01285A publication Critical patent/IN2012DN01285A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

An angiogenesis regulating composition used to treat/prevent an angiogenic disease in a subject  that contains in an effective amount at least one of nitrate  nitrite  and a compound convertible into nitrate or nitrite after the compound is absorbed into the subject  and an angiogenesis regulation method administering to a subject a composition containing as an active ingredient at least one of nitrate  nitrite  and a compound convertible into nitrate or nitrite after the compound is absorbed into the subject  provide a composition effective in treating and preventing angiogenic diseases  that can medically control angiogenic diseases  and medically regulate angiogenesis in ophthalmologic diseases in particular  and allows treatment without inhibiting physiological neovascularization  with a limited side effect and significantly safely  and an angiogenesis regulation method using the same.
IN1285DEN2012 2009-07-17 2010-07-12 IN2012DN01285A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009168928 2009-07-17
JP2010128057A JP5791064B2 (en) 2009-07-17 2010-06-03 Pharmaceutical composition
PCT/JP2010/061768 WO2011007755A1 (en) 2009-07-17 2010-07-12 Angiogenesis-regulating composition and angiogenesis regulation method

Publications (1)

Publication Number Publication Date
IN2012DN01285A true IN2012DN01285A (en) 2015-05-15

Family

ID=43449363

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1285DEN2012 IN2012DN01285A (en) 2009-07-17 2010-07-12

Country Status (6)

Country Link
US (2) US20120114768A1 (en)
EP (1) EP2455091A4 (en)
JP (1) JP5791064B2 (en)
CN (1) CN102470146B (en)
IN (1) IN2012DN01285A (en)
WO (1) WO2011007755A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2888899C (en) 2012-10-24 2023-02-21 Japan Innovative Therapeutics, Inc. Use of tryptase inhibitors in the treatment retinopathy of prematurity
JP6042197B2 (en) * 2012-12-11 2016-12-14 エア・ウォーター株式会社 Lung disorder treatment
JP6153838B2 (en) * 2013-10-04 2017-06-28 エア・ウォーター株式会社 Vascular permeability inhibitor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731294A (en) 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
JPH09508892A (en) * 1993-11-17 1997-09-09 マサチューセッツ インスティテュート オブ テクノロジー Method for inhibiting angiogenesis using heparinase
JPH10273450A (en) * 1997-03-27 1998-10-13 Toagosei Co Ltd Therapeutic agent for intraocular neovascular disease
JP4777489B2 (en) * 1997-03-31 2011-09-21 ザ チルドレンズ メディカル センター コーポレーション Nitrosylation to inactivate apoptotic enzymes
JP2002507567A (en) * 1998-03-25 2002-03-12 ラージ スケール バイオロジー コーポレイション Benzoic acid derivatives for inhibiting angiogenesis
EP1161532A1 (en) * 1999-03-01 2001-12-12 Human Genome Sciences, Inc. Human serpin proteins
CA2378257A1 (en) * 1999-08-10 2001-02-15 William E. Sponsel Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
JP4210826B2 (en) 2001-01-19 2009-01-21 参天製薬株式会社 Angiogenesis inhibitors containing urea derivatives as active ingredients
US20070135380A1 (en) * 2005-08-12 2007-06-14 Radiorx, Inc. O-nitro compounds, pharmaceutical compositions thereof and uses thereof
US20080069904A1 (en) * 2006-07-18 2008-03-20 Oronsky Bryan T Inhibition of angiogenesis through nitric oxide tachyphylaxis
JP2008110950A (en) 2006-10-31 2008-05-15 Japan Health Science Foundation Method for treating diabetic retinopathy
EP2114417A4 (en) * 2007-02-26 2014-04-02 Heartbeet Ltd New use of nitrites and nitrates and compositions containing these
NZ590454A (en) * 2008-07-31 2012-09-28 Nicox Sa Glucocorticoids attached to nitrate esters via an aromatic linker in position 21 and their use in ophthalmology
US20100197702A1 (en) * 2009-02-04 2010-08-05 Hellberg Mark R Ophthalmic composition with nitric oxide donor compound and method of forming and using same

Also Published As

Publication number Publication date
WO2011007755A1 (en) 2011-01-20
JP2011037830A (en) 2011-02-24
US20120114768A1 (en) 2012-05-10
US8974836B2 (en) 2015-03-10
US20130251823A1 (en) 2013-09-26
CN102470146B (en) 2014-09-10
EP2455091A1 (en) 2012-05-23
JP5791064B2 (en) 2015-10-07
CN102470146A (en) 2012-05-23
EP2455091A4 (en) 2012-12-19

Similar Documents

Publication Publication Date Title
WO2009129509A3 (en) Methods and compositions for treating post-operative pain comprising a local anesthetic
WO2009129437A3 (en) Methods and compositions for treating post-operative pain comprising clonidine
MY160894A (en) Oligosaccharide composition for treating skin diseases
MX2022004012A (en) Catheter locking solution and catheter locking therapy.
BR112014015482A2 (en) phenyl carbamate compounds for use in the alleviation or treatment of pain and neuropathic pain
MX2011007854A (en) Methods for treating acute myocardial infarctions and associated disorders.
WO2009106991A3 (en) Pyridazine derivatives and their use as therapeutic agents in the treatment of skin disorders
MX2013013809A (en) Expandable devices coated with a paclitaxel composition.
WO2006098603A3 (en) Composition comprising isoorientin for suppressing histamine
GB2476202A (en) Novel choline cocrystal of epalrestat
NZ586302A (en) Pre-surgical treatment using brimonidine applied topically to reduce bleeding or bruising
EP2490700A4 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
SG10201807789WA (en) Vaginal composition and use thereof
MX2024000828A (en) Isoxazoline parasiticide formulations and methods for treating blepharitis.
MX369117B (en) Selective ep4 receptor agonistic substance for treatment of cancer.
MX2009012486A (en) A liquid formulation for administering nicotine.
IN2012DN01285A (en)
WO2012106058A3 (en) Animal treatments
HRP20190562T1 (en) Compositions for treating heartworm infestation
PL2165704T3 (en) Use of alverine for the treatment of cutaneous affections
WO2009131850A3 (en) Pai-1 expression and activity inhibitors for the treatment of ocular disorders
MX2021016055A (en) Isoxazoline parasiticide formulations and methods for treating blepharitis.
MX2018011539A (en) Treatment of skin conditions and diseases associated with microbial biofilms.
MX2020007817A (en) Sleep disorder treatment and prevention.
MX2016008546A (en) Keloid reduction using topical allantoin.